SG46382A1 - Amylin for treatment of bone disorders - Google Patents

Amylin for treatment of bone disorders

Info

Publication number
SG46382A1
SG46382A1 SG1996003975A SG1996003975A SG46382A1 SG 46382 A1 SG46382 A1 SG 46382A1 SG 1996003975 A SG1996003975 A SG 1996003975A SG 1996003975 A SG1996003975 A SG 1996003975A SG 46382 A1 SG46382 A1 SG 46382A1
Authority
SG
Singapore
Prior art keywords
amylin
bone
treatment
disorders
variants
Prior art date
Application number
SG1996003975A
Other languages
English (en)
Inventor
Iain Macintyre
Original Assignee
Amylin Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals Inc filed Critical Amylin Pharmaceuticals Inc
Publication of SG46382A1 publication Critical patent/SG46382A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/225Calcitonin gene related peptide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/23Calcitonins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/28Insulins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/02Nutrients, e.g. vitamins, minerals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Nutrition Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
SG1996003975A 1989-07-08 1990-07-09 Amylin for treatment of bone disorders SG46382A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898915712A GB8915712D0 (en) 1989-07-08 1989-07-08 Medical treatment

Publications (1)

Publication Number Publication Date
SG46382A1 true SG46382A1 (en) 1998-02-20

Family

ID=10659773

Family Applications (1)

Application Number Title Priority Date Filing Date
SG1996003975A SG46382A1 (en) 1989-07-08 1990-07-09 Amylin for treatment of bone disorders

Country Status (12)

Country Link
EP (1) EP0408284B1 (da)
JP (1) JPH04500691A (da)
AT (1) ATE137975T1 (da)
CA (1) CA2020752C (da)
DE (1) DE69026986T2 (da)
DK (2) DK0408284T3 (da)
ES (1) ES2088971T3 (da)
GB (1) GB8915712D0 (da)
GR (1) GR3020680T3 (da)
IE (1) IE62625B1 (da)
SG (1) SG46382A1 (da)
WO (1) WO1991000710A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2109794A1 (en) * 1991-05-24 1992-11-26 Timothy J. Rink Amylin and possibly insulin containing composition for the treatment of anorexia and related states
WO1992020366A1 (en) * 1991-05-24 1992-11-26 Amylin Pharmaceuticals, Inc. Insulin and amylin containing composition for the treatment of insulin deficient mammals
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US6001884A (en) * 1991-08-23 1999-12-14 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5858684A (en) * 1991-08-23 1999-01-12 The Brigham And Women's Hospital, Inc. Method of screening calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1993019774A1 (en) * 1992-04-03 1993-10-14 Amylin Pharmaceuticals, Inc. Amylin and possibly insulin containing composition for the treatment of anorexia and related states
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
EP1203761B1 (en) 1994-10-21 2005-01-19 Nps Pharmaceuticals, Inc. Calcium receptor-active compounds
DK0907631T3 (da) 1996-05-01 2003-09-22 Nps Pharma Inc Uorganiske ionreceptoraktive forbindelser
WO1999016406A2 (en) * 1997-09-26 1999-04-08 Auckland Uniservices Limited Therapeutic method

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4925833A (en) * 1983-12-29 1990-05-15 The Research Foundation Of State University Of New York Use of tetracycline to enhance bone protein synthesis and/or treatment of osteoporosis
GB8407907D0 (en) * 1984-03-27 1984-05-02 Sandoz Ltd Organic compounds
US4588716A (en) * 1984-05-04 1986-05-13 Wisconsin Alumni Research Foundation Method for treating metabolic bone disease in mammals
JPS62129297A (ja) * 1985-08-09 1987-06-11 Toyo Jozo Co Ltd カルシトニン遺伝子関連ペプチド誘導体
US4677132A (en) * 1986-03-12 1987-06-30 American Home Products Corporation Inhibition of bone resorption by etodolac
GB8720115D0 (en) * 1987-08-26 1987-09-30 Cooper G J S Treatment of diabetes mellitus
HU203198B (en) * 1987-10-26 1991-06-28 Sandoz Ag Process for producing pharmaceutical compositions having immunity-inhibiting, monokin-, particularly interleukin-1-inhibiting effect
JP2944117B2 (ja) * 1988-07-22 1999-08-30 エチル・コーポレーション 骨の処置におけるケイ素化合物

Also Published As

Publication number Publication date
GB8915712D0 (en) 1989-08-31
CA2020752A1 (en) 1992-01-10
GR3020680T3 (en) 1996-10-31
DK40191D0 (da) 1991-03-07
DK0408284T3 (da) 1996-06-03
DK40191A (da) 1991-03-07
CA2020752C (en) 1996-12-24
ES2088971T3 (es) 1996-10-01
EP0408284A2 (en) 1991-01-16
JPH04500691A (ja) 1992-02-06
ATE137975T1 (de) 1996-06-15
DE69026986D1 (de) 1996-06-20
WO1991000710A1 (en) 1991-01-24
IE62625B1 (en) 1995-02-22
EP0408284A3 (en) 1992-01-08
EP0408284B1 (en) 1996-05-15
IE902494A1 (en) 1991-02-13
DE69026986T2 (de) 1996-10-02

Similar Documents

Publication Publication Date Title
EP0408284A3 (en) Amylin for treatment of bone disorders
CS949087A2 (en) Stabilizer for thigh-bone's collum and upper end fracture treatment
PL341112A1 (en) Methods of providing postmenopausal treatment to female patients using very low doses of oestrogen
CA2011751A1 (en) Fixation plate
EP0309100A3 (en) Use of amylin or cgrp for the treatment of diabetes mellitus
GB8618651D0 (en) Colles fracture brace
AU1808488A (en) Compounds for the treatment of alzheimer's disease
EP0313295A3 (en) Substituted tetralins, chromans and related compounds in the treatment of asthma, arthritis and related diseases
PT84662A (en) Process for the preparation of pharmaceutical compositions containing 7,alpha-]1(s)-hydroxy-1-methylbuthyl"-6,14-endoetheno-6,7,8,14-tetrahydro-oripavine (etorphine)
GB8621816D0 (en) Therapeutic composition
HUT59833A (en) Process for producing pharmaceutical compositions containing calcitoninogene like peptides for treating erectional disfunctions
JPS6471889A (en) Novel 6-acyl-(6h)-dibenzo(c,e)(1,2)oxaphosphorine- 6-oxide, manufacture and use as photoinitiator
MY103790A (en) Novel compound for the treatment of several bone affecting diseases
EP0330756A3 (en) Thienotricyclics for the treatment of bronchial diseases
EP0486584A4 (en) Dopaminergic neurotrophic factor for treatment of parkinson's disease
GB8903565D0 (en) Bone cements
EP0295827A3 (en) Use of 24,25-dihydroxy-cholecalciferol in mending bone fractures
EP0301546A3 (en) Compositions containing and use of etiocholanedione
NZ221473A (en) Octapeptide somatostatin analogue "octreotide" in nasal compositions
FR2649310B1 (fr) Broche intra-focale a effet de reduction pour l'osteosynthese des fractures
EP0173527A3 (en) Insulin-selective somatostatin analogs
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
GB8908549D0 (en) Liquid leather treatment composition
Ashizuka Mechanical Properties of Phosphate Glasses and Ceramics
Yokoyama et al. Prognosis of Fracture of the Neck of the Femur